Gynaecologic Oncology
April 2015
This bulletin covers aspects of gynaecological cancers and should be of interest to multidisciplinary
teams working in this area.
Sections can include:
 Combined Modality Therapies
 Drug Therapy
 Pathology, Staging, Polymorphisms & Biomarkers
 Prognosis, Survival & Risk Factors
 Radiotherapy & Imaging
 Supportive Care & Symptom Management
 Surgery
Many of the following articles are available online via the NHS Scotland Knowledge Network.
Please use the links where provided and your ATHENS password. A complete list of
available online journals and registration for ATHENS can be found at
www.knowledge.scot.nhs.uk/
If the article you require is not available via the NHS Scotland Knowledge Network and you
would like to request a print copy, please submit your request online at
www.quest.scot.nhs.uk
This bulletin contains a selection of material gathered from a search of the evidence base, and is
not intended to be comprehensive. Professional judgment should be exercised when appraising
the material. The Library takes no responsibility for the wording, content and accuracy of the
information supplied, which has been extracted in good faith from reputable sources. NHSGGC is
not responsible for the content of external internet sites.
Compiled by:
Kirsty Coltart
Subject Librarian
Beatson West of Scotland Cancer Centre
0141 301 7285, kirsty.coltart@ggc.scot.nhs.uk
1
Gynaecologic Oncology, April 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
General
Battista MJ, Schmidt M, Rieks N, et al. (2015). Adjuvant treatment decisions for patients
with endometrial cancer in Germany: results of the nationwide AGO pattern of care
studies from the years 2013, 2009 and 2006. Journal of Cancer Research & Clinical Oncology
141,3:555-562.
Bradford LS, Rauh-Hain JA, Schorge J, et al. (2015). Advances in the management of
recurrent endometrial cancer. American Journal of Clinical Oncology 38,2:206-212.
Gadducci A, Fabrini MG, Lanfredini N, et al. (2015). Squamous cell carcinoma of the vagina:
natural history, treatment modalities and prognostic factors. Critical Reviews in OncologyHematology 93,3:211-224.
Groen RS, Gershenson DM and Fader AN. (2015). Updates and emerging therapies for rare
epithelial ovarian cancers: one size no longer fits all. Gynecologic oncology 136,2:373-383.
How JA, Abitbol J, Lau S, et al. (2015). The impact of qualitative research on gynaecologic
oncology guidelines. Journal of Obstetrics & Gynaecology Canada: JOGC 37,2:138-144.
Koh WJ, Greer BE, Abu-Rustum NR, et al. (2015). Cervical cancer, version 2.2015. Journal of
the National Comprehensive Cancer Network 13,4:395-404.
Mahner S, Jueckstock J, Hilpert F, et al. (2015). Adjuvant therapy in lymph node-positive
vulvar cancer: the AGO-CaRE-1 study. Journal of the National Cancer Institute 107,3:
Preston NJ, Wilson N, Wood NJ, et al. (2015). Patient-reported outcome measures for use in
gynaecological oncology: a systematic review. BJOG: An International Journal of Obstetrics
& Gynaecology 122,5:615-622.
Combined Modality Therapies
Fotopoulou C, Kraetschell R, Dowdy S, et al. (2015). Surgical and systemic management of
endometrial cancer: an international survey. Archives of Gynecology & Obstetrics 291,4:897905.
Hanna TP, Shafiq J, Delaney GP, et al. (2015). The population benefit of radiotherapy for
cervical cancer: Local control and survival estimates for optimally utilized radiotherapy
and chemoradiation. Radiotherapy & Oncology 114,3:389-394.
Spiliotis J, Halkia E, Lianos E, et al. (2015). Cytoreductive Surgery and HIPEC in Recurrent
Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study. Annals of Surgical
Oncology 22,5:1570-1575.
Drug & Targeted Therapy
Edwards SJ, Barton S, Thurgar E, et al. (2015). Topotecan, pegylated liposomal doxorubicin
hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or
refractory ovarian cancer: a systematic review and economic evaluation. Health
technology assessment (Winchester, England) 19,7:1-480.
Garces AH, Dias MS, Paulino E, et al. (2015). Treatment of ovarian cancer beyond
2
Gynaecologic Oncology, April 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
chemotherapy: are we hitting the target? Cancer Chemotherapy & Pharmacology 75,2:221234.
Hensley ML, Miller A, O'Malley DM, et al. (2015). Randomized Phase III Trial of Gemcitabine
Plus Docetaxel Plus Bevacizumab or Placebo As First-Line Treatment for Metastatic
Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study.
Journal of Clinical Oncology 33,10:1180-1185.
Hong SH, Lee S, Kim HG, et al. (2015). Phase II study of gemcitabine and vinorelbine as
second- or third-line therapy in patients with primary refractory or platinum-resistant
recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group
(KCSG)_KCSG GY10-10. Gynecologic oncology 136,2:212-217.
Kummar S, Oza AM, Fleming GF, et al. (2015). Randomized Trial of Oral Cyclophosphamide
and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube
Cancers, or BRCA-Mutant Ovarian Cancer. Clinical Cancer Research 21,7:1574-1582.
Mahner S, Meier W, du Bois A, et al. (2015). Carboplatin and pegylated liposomal
doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer
patients: results from a subset analysis of the CALYPSO phase III trial. European journal of
cancer 51,3:352-358.
Markman, M. (2015). Maintenance chemotherapy in the management of epithelial ovarian
cancer. Cancer & Metastasis Reviews 34,1:11-17.
Matsumoto K, Katsumata N, Shibata T, et al. (2015). Phase II trial of oral etoposide plus
intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian
cancer (JCOG0503). Gynecologic oncology 136,2:218-223.
Penson RT, Huang HQ, Wenzel LB, et al. (2015). Bevacizumab for advanced cervical
cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG OncologyGynecologic Oncology Group protocol 240). Lancet Oncology 16,3:301-311.
Satoh T, Aoki Y, Kasamatsu T, et al. (2015). Administration of standard-dose BEP regimen
(bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour.
European journal of cancer 51,3:340-351.
Simpkins F, Drake R, Escobar PF, et al. (2015). A phase II trial of paclitaxel, carboplatin, and
bevacizumab in advanced and recurrent endometrial carcinoma (EMCA). Gynecologic
oncology 136,2:240-245.
Slomovitz BM, Jiang Y, Yates MS, et al. (2015). Phase II Study of Everolimus and Letrozole
in Patients With Recurrent Endometrial Carcinoma. Journal of Clinical Oncology 33,8:930936.
Vasconcelos I, Olschewski J, Braicu I, et al. (2015). Limited efficacy of platinum-based
adjuvant treatment on the outcome of borderline ovarian tumors. European Journal of
Obstetrics, Gynecology, & Reproductive Biology 186,26-33.
Vasconcelos I, Olschewski J, Braicu I, et al. (2015). A meta-analysis on the impact of
platinum-based adjuvant treatment on the outcome of borderline ovarian tumors with
invasive implants. Oncologist 20,2:151-158.
Pathology, Staging, Polymorphisms & Biomarkers
3
Gynaecologic Oncology, April 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Gilks CB, Irving J, Kobel M, et al. (2015). Incidental nonuterine high-grade serous
carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin
of high-grade serous carcinomas. American Journal of Surgical Pathology 39,3:357-364.
Growdon WB, Groeneweg J, Byron V, et al. (2015). HER2 over-expressing high grade
endometrial cancer expresses high levels of p95HER2 variant. Gynecologic oncology
137,1:160-166.
Howitt BE, Hanamornroongruang S, Lin DI, et al. (2015). Evidence for a dualistic model of
high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial
carcinoma. American Journal of Surgical Pathology 39,3:287-293.
Rai N, Nevin J, Downey G, et al. (2015). Outcomes following implementation of symptom
triggered diagnostic testing for ovarian cancer. European Journal of Obstetrics, Gynecology,
& Reproductive Biology 187,64-69.
Solmaz U, Mat E, Dereli ML, et al. (2015). Lymphovascular space invasion and positive
pelvic lymph nodes are independent risk factors for para-aortic nodal metastasis in
endometrioid endometrial cancer. European Journal of Obstetrics, Gynecology, &
Reproductive Biology 186,63-67.
Prognosis, Survival & Risk Factors
Balasubramaniam K, Ravn P, Larsen PV, et al. (2015). Specific and unspecific gynecological
alarm symptoms--prevalence estimates in different age groups: a population-based
study. Acta Obstetricia et Gynecologica Scandinavica 94,2:191-197.
Bendifallah S, Canlorbe G, Collinet P, et al. (2015). Just how accurate are the major risk
stratification systems for early-stage endometrial cancer?. British journal of cancer
112,5:793-801.
Bristow RE, Chang J, Ziogas A, et al. (2015). Sociodemographic disparities in advanced
ovarian cancer survival and adherence to treatment guidelines. Obstetrics & Gynecology
125,4:833-842.
Creutzberg CL, van Stiphout RG, Nout RA, et al. (2015). Nomograms for prediction of
outcome with or without adjuvant radiation therapy for patients with endometrial cancer:
a pooled analysis of PORTEC-1 and PORTEC-2 trials. International journal of radiation
oncology, biology, physics 91,3:530-539.
Lee JY, Kim TH, Suh DH, et al. (2015). Impact of guideline adherence on patient outcomes
in early-stage epithelial ovarian cancer. European Journal of Surgical Oncology 41,4:585591.
Li K, Husing A, Fortner RT, et al. (2015). An epidemiologic risk prediction model for ovarian
cancer in Europe: the EPIC study. British journal of cancer 112,Suppl:1257-1265.
Matsuo K, Yoshino K, Hasegawa K, et al. (2015). Survival outcome of stage I ovarian clear
cell carcinoma with lympho-vascular space invasion. Gynecologic oncology 136,2:198-204.
Rahman B, Meisel SF, Fraser L, et al. (2015). Population-based genetic risk prediction and
stratification for ovarian cancer: views from women at high risk. Familial Cancer 14,1:135144.
4
Gynaecologic Oncology, April 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Rutten MJ, van de Vrie R, Bruining A, et al. (2015). Predicting surgical outcome in patients
with International Federation of Gynecology and Obstetrics stage III or IV ovarian cancer
using computed tomography: a systematic review of prediction models. International
Journal of Gynecological Cancer 25,3:407-415.
van der Heijden E, Lopes AD, Bryant A, et al. (2015). Follow-up strategies after treatment
(large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial
neoplasia (CIN): Impact of human papillomavirus (HPV) test. Cochrane Database of
Systematic Reviews 1,010757.
Radiotherapy & Imaging
Gill BS, Kim H, Houser CJ, et al. (2015). MRI-guided high-dose-rate intracavitary
brachytherapy for treatment of cervical cancer: the University of Pittsburgh experience.
International journal of radiation oncology, biology, physics 91,3:540-547.
Harkenrider MM, Block AM, Siddiqui ZA, et al. (2015). The role of vaginal cuff brachytherapy
in endometrial cancer. Gynecologic oncology 136,2:365-372.
Mazeron R, Champoudry J, Gilmore J, et al. (2015). Intrafractional organs movement in
three-dimensional image-guided adaptive pulsed-dose-rate cervical cancer
brachytherapy: assessment and dosimetric impact. Brachytherapy 14,2:260-266.
Palsdottir K, Fischerova D, Franchi D, et al. (2015). Preoperative prediction of lymph node
metastasis and deep stromal invasion in women with invasive cervical cancer:
prospective multicenter study using 2D and 3D ultrasound. Ultrasound in Obstetrics &
Gynecology 45,4:470-475.
Patankar SS, Tergas AI, Deutsch I, et al. (2015). High versus low-dose rate brachytherapy
for cervical cancer. Gynecologic oncology 136,3:534-541.
Xie WJ, Wu X, Xue RL, et al. (2015). More Accurate Definition of Clinical Target Volume
Based on the Measurement of Microscopic Extensions of the Primary Tumor Toward the
Uterus Body in International Federation of Gynecology and Obstetrics Ib-IIa Squamous
Cell Carcinoma of the Cervix. International journal of radiation oncology, biology, physics
91,1:206-212.
Supportive Care & Symptom Management
Bober SL, Recklitis CJ, Bakan J, et al. (2015). Addressing sexual dysfunction after riskreducing salpingo-oophorectomy: effects of a brief, psychosexual intervention. Journal of
Sexual Medicine 12,1:189-197.
Cook O, McIntyre M and Recoche K. (2015). Exploration of the role of specialist nurses in
the care of women with gynaecological cancer: a systematic review. Journal of Clinical
Nursing 24,5-6:683-695.
Crawford JJ, Vallance JK, Holt NL, et al. (2015). Associations between exercise and
posttraumatic growth in gynecologic cancer survivors. Supportive Care in Cancer
23,3:705-714.
Fanfani F, Costantini B, Mascilini F, et al. (2015). Early postoperative bladder training in
patients submitted to radical hysterectomy: is it still necessary? A randomized trial.
5
Gynaecologic Oncology, April 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Archives of Gynecology & Obstetrics 291,4:883-888.
Hoeck B, Ledderer L and Hansen HP. (2015). Involvement of patients with lung and
gynecological cancer and their relatives in psychosocial cancer rehabilitation: a narrative
review. The Patient: Patient-Centered Outcomes Research 8,2:127-143.
Ishida K, Ishida J and Kiyoko K. (2015). Psychosocial Reaction Patterns to Alopecia in
Female Patients with Gynecological Cancer undergoing Chemotherapy. Asian Pacific
Journal of Cancer Prevention: Apjcp 16,3:1225-1233.
Kim SI, Lee Y, Lim MC, et al. (2015). Quality of life and sexuality comparison between
sexually active ovarian cancer survivors and healthy women. Journal of Gynecologic
Oncology 26,2:148-154.
Laterza RM, Sievert KD, de Ridder D, et al. (2015). Bladder function after radical
hysterectomy for cervical cancer. Neurourology & Urodynamics 34,4:309-315.
Lu D, Wang X and Shi G. (2015). Perioperative enhanced recovery programmes for
gynaecological cancer patients. Cochrane Database of Systematic Reviews 3,008239.
Meyer LA, Nick AM, Shi Q, et al. (2015). Perioperative trajectory of patient reported
symptoms: A pilot study in gynecologic oncology patients. Gynecologic oncology
136,3:440-445.
Peipins LA, McCarty F, Hawkins NA, et al. (2015). Cognitive and affective influences on
perceived risk of ovarian cancer. Psycho-oncology 24,3:279-286.
Pfaendler KS, Wenzel L, Mechanic MB, et al. (2015). Cervical cancer survivorship: long-term
quality of life and social support. Clinical therapeutics 37,1:39-48.
Stafford L, Thomas N, Foley E, et al. (2015). Comparison of the acceptability and benefits of
two mindfulness-based interventions in women with breast or gynecologic cancer: a pilot
study. Supportive Care in Cancer 23,4:1063-1071.
Vermeer WM, Bakker RM, Kenter GG, et al. (2015). Sexual issues among cervical cancer
survivors: how can we help women seek help?. Psycho-oncology 24,4:458-464.
Wenzel L, Osann K, Hsieh S, et al. (2015). Psychosocial telephone counseling for survivors
of cervical cancer: results of a randomized biobehavioral trial. Journal of Clinical Oncology
33,10:1171-1179.
Werner-Lin A, Ratner R, Hoskins LM, et al. (2015). A survey of genetic counselors about the
needs of 18-25 year olds from families with hereditary breast and ovarian cancer
syndrome. Journal of Genetic Counseling 24,1:78-87.
Surgery
Arsene E, Bleu G, Merlot B, et al. (2015). Implications of a two-step procedure in surgical
management of patients with early-stage endometrioid endometrial cancer. Journal of
Gynecologic Oncology 26,2:125-133.
Baker J, Janda M, Gebski V, et al. (2015). Lower preoperative quality of life increases
postoperative risk of adverse events in women with endometrial cancer: Results from the
LACE trial. Gynecologic oncology 137,1:102-105.
6
Gynaecologic Oncology, April 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Corrado G, Fanfani F, Ghezzi F, et al. (2015). Mini-laparoscopic versus robotic radical
hysterectomy plus systematic pelvic lymphadenectomy in early cervical cancer patients.
A multi-institutional study. European Journal of Surgical Oncology 41,1:136-141.
Iyer R, Gentry-Maharaj A, Nordin A, et al. (2015). Predictors of complications in
gynaecological oncological surgery: a prospective multicentre study (UKGOSOC-UK
gynaecological oncology surgical outcomes and complications). British journal of cancer
112,3:475-484.
Kavallaris A, Zygouris D, Dafopoulos A, et al. (2015). Nerve sparing radical hysterectomy in
early stage cervical cancer. Latest developments and review of the literature. European
journal of gynaecological oncology 36,1:5-9.
Kim HS, Kim K, Ryoo SB, et al. (2015). Conventional versus nerve-sparing radical surgery
for cervical cancer: a meta-analysis. Journal of Gynecologic Oncology 26,2:100-110.
Please note that the journal articles you are accessing are subject to the terms and conditions
imposed by the publisher, so there will be a limit on the number of articles an individual may
download or print from a single issue of a journal. You can consult your local NHSGGC library with
any queries.
If you have any questions regarding this or any other library services please contact Library staff –
contact details are at the beginning of the bulletin.
Sources used for this bulletin: OVID databases, SIGN, NICE, Healthcare Improvement Scotland
7
Gynaecologic Oncology, April 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network